Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2026)

Royalty Pharma has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $17.5 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $17.5 million, down 6.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.5 million (down 6.02% YoY), and the FY2025 annual result was $53.2 million, down 22.5% from the prior year.
• Other Accumulated Expenses came in at $17.5 million for Q1 2026 at Royalty Pharma, down from $53.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $97.5 million in Q2 2024 to a low of $3.1 million in Q2 2025.
• The 5-year median for Other Accumulated Expenses is $17.5 million (2026), against an average of $29.6 million.
• Across the five-year window, Other Accumulated Expenses soared 503.08% in 2024 and plunged 96.85% in 2025, its largest moves.
• Royalty Pharma's Other Accumulated Expenses stood at $12.4 million in 2022, then dropped by 8.27% to $11.4 million in 2023, then jumped by 503.08% to $68.6 million in 2024, then fell by 22.5% to $53.2 million in 2025, then tumbled by 67.12% to $17.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $17.5 million (Q1 2026), $53.2 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.